To explore the inhibitory effect of ginkgolide B (GB) on MH7A human fibroblast-like synoviocytes (FLS) and its potential mechanism. Firstly, 20 μg/L tumor necrosis factor-α (TNF-α) was pretreated with MH7A to establish a cell model of arthritis. After incubation of MH7A cells with various concentrations of GB, CCK-8 assay, Transwell assay, and flow cytometry (FCM) were separately used to detect cell viability, cell invasion, and cell apoptosis rate and cell cycle; Real-time quantitative PCR and Western blot assay were performed to detect the apoptosis- and cycle-related gene transcriptions and protein expressions, respectively. The results showed that compared with the control group, GB dose- and time-dependently suppressed cell viability to a greater extent; GB significantly reduced cell invasive ability and increased cell apoptosis rate and proportion of G0/G1 phase in MH7A cells, along with increased transcription levels of Bcl-2-associated X protein (Bax) and p21 mRNA and decreased transcription levels of Bcl-2, myeloid cell leukemia 1(Mcl-1), protein kinase B (PKB; AKT), IP3K, Cyclin D1 and cyclin-dependent kinase 4 (CDK4) mRNA; GB remarkably increased expression levels of Bax, p21, and cleaved-Caspase 3 protein and decreased expression levels of Bcl-2, Mcl-1, p-AKT, p-PI3K, Cyclin D1, and CDK4 protein, with decreased ratios of p-PI3K/PI3K, p-AKT/AKT, and Bcl-2/Bax. In conclusion, GB blocks the G1-to-S cell cycle transition, suppresses cell viability and cell invasion and induces cell apoptosis of MH7A human RA-FLS via suppressing the PI3K/AKT signaling pathway.

Objective:To summarize the best evidence of the management of enteral nutrition feeding intolerance (EFI) in postoperative patients with gastric cancer, in order to facilitate the best evidence-based clinical practice.Methods:According to the "6S" evidence pyramid model, relevant guide websites, evidence-based databases, relevant society websites and original literature databases at home and abroad were systematically searched for relevant literature on postoperative tube feeding EFI for gastric cancer patients, and the search time was from the establishment of the database to July 29, 2023. The quality assessment was conducted by two researchers by using AGREE II for guidelines, JBI evidence-based health care center evaluate standards for systematic review and expert consensus.Results:An initial searching of 994 literatures resulted in 23 literatures that met inclusion criteria. Finally, a total of 21 pieces of evidence were summarized from 5 aspects including basic requirements, assessment, interventions, notes and health education.Conclusions:This study summarized the best evidence of management of tube EFI in postoperative gastric cancer patients. Clinical staff should transfer and apply these evidences based on the actual clinical situation, demands, patients' condition of disease and treatment and their preferences, tto reduce the incidence of postoperative tube feeding EFI in patients with gastric cancer.

Objective:To summarize the best evidence of the management of enteral nutrition feeding intolerance (EFI) in postoperative patients with gastric cancer, in order to facilitate the best evidence-based clinical practice.Methods:According to the "6S" evidence pyramid model, relevant guide websites, evidence-based databases, relevant society websites and original literature databases at home and abroad were systematically searched for relevant literature on postoperative tube feeding EFI for gastric cancer patients, and the search time was from the establishment of the database to July 29, 2023. The quality assessment was conducted by two researchers by using AGREE II for guidelines, JBI evidence-based health care center evaluate standards for systematic review and expert consensus.Results:An initial searching of 994 literatures resulted in 23 literatures that met inclusion criteria. Finally, a total of 21 pieces of evidence were summarized from 5 aspects including basic requirements, assessment, interventions, notes and health education.Conclusions:This study summarized the best evidence of management of tube EFI in postoperative gastric cancer patients. Clinical staff should transfer and apply these evidences based on the actual clinical situation, demands, patients' condition of disease and treatment and their preferences, tto reduce the incidence of postoperative tube feeding EFI in patients with gastric cancer.